Wenbin Jin

Beijing, 100730, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Development and Advantages of O-(Carboxymethyl)-L-tyrosine-Based PSMA-Targeting Theranostics for Prostate Cancer.

Development and Advantages of O-(Carboxymethyl)-L-tyrosine-Based PSMA-Targeting Theranostics for Prostate Cancer.

Journal: Journal of medicinal chemistry

Published: July 08, 2026

Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics.

Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics.

Journal: Bioorganic chemistry

Published: June 01, 2026

Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention.

Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention.

Journal: Molecular pharmaceutics

Published: April 29, 2026

Preclinical and Initial Clinical Evaluation of 68Ga/177Lu-Labeled Heterodimer Agents Targeting Somatostatin Receptors and Integrin αVβ3.

Preclinical and Initial Clinical Evaluation of 68Ga/177Lu-Labeled Heterodimer Agents Targeting Somatostatin Receptors and Integrin αVβ3.

Journal: Molecular pharmaceutics

Published: December 17, 2025

First-in-human study of a novel bifunctional PET tracer [68Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia.

First-in-human study of a novel bifunctional PET tracer [68Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 12, 2025

First-in-Human PET Imaging of Prostate Cancer Using [68Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [68Ga]Ga-AZ-NI-093.

First-in-Human PET Imaging of Prostate Cancer Using [68Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [68Ga]Ga-AZ-NI-093.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: June 23, 2025

PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC).

PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC).

Journal: Journal of medicinal chemistry

Published: January 10, 2025

Development of [68Ga]Ga/[177Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention.

Development of [68Ga]Ga/[177Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention.

Journal: Journal of medicinal chemistry

Published: December 23, 2024

Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.

Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.

Journal: Clinical nuclear medicine

Published: November 05, 2024

68Ga/177Lu-Labeled Bivalent Agents for Targeting Hypoxia and PSMA-Binding in Prostate Cancer.

68Ga/177Lu-Labeled Bivalent Agents for Targeting Hypoxia and PSMA-Binding in Prostate Cancer.

Journal: Journal of medicinal chemistry

Published: July 29, 2024

Novel [68Ga/177Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy.

Novel [68Ga/177Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy.

Journal: Molecular pharmaceutics

Published: June 10, 2024

First-in-human study of dosimetry, safety and efficacy for [177Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases.

First-in-human study of dosimetry, safety and efficacy for [177Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 16, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026